In accordance with our hypothesis, it has been already reported that exosomes secreted by breast cancer cells carrying HER2 antigen, the target of Trastuzumab, contribute to drug sequestration and compromise its efficacy [18]. The gene discussed is ERBB2; the disease is breast carcinoma.